Atypical depression shares genetic predisposition with immuno-metabolic traits: a population-based study

Isabella Badini[1], Jonathan R.I. Coleman[1,2], Saskia P. Hagenaars[1], Matthew Hotopf[2,3,4], Gerome Breen[1,2], Cathryn M. Lewis[1,2], Chiara Fabbri[1]

1 Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom

2 National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.

3 Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

4 South London and Maudsley NHS Foundation Trust, London, UK

Running title: atypical depression and immune-metabolic traits

Corresponding author:
Chiara Fabbri MD PhD
Social, Genetic and Developmental Psychiatry Centre
Institute of Psychiatry, Psychology and Neuroscience
King's College London
De Crespigny Park,
Denmark Hill, London,
United Kingdom, SE5 8AF
chiara.fabbri@kcl.ac.uk
chiara.fabbri@yahoo.it

Abstract

Background: Depression is a highly prevalent and heterogenous disorder. Clinical heterogeneity may reflect different underlying biological mechanisms. This study aims to determine whether atypical depression shows higher heritability and different degree of overlap with polygenic risk for cardio- and immuno- metabolic traits than non-atypical depression.

Methods: Data included 30,069 individuals from the UK Biobank who met criteria for lifetime major depression. Participants reporting both hypersomnia and weight gain were classified as atypical cases (N = 1,854), and the others as non-atypical cases (N = 28,215). Non-atypical cases were further classified as typical depression (i.e. insomnia and weight loss; N = 10,142). Polygenic risk scores (PRS) for 21 traits were generated using genome-wide summary statistics (Bonferroni corrected $p=2.2 \times 10^{-4}$). Single nucleotide polymorphism (SNP)-based heritability of atypical and typical depression was estimated.

Results: Atypical depression had a higher polygenic risk for BMI (OR=1.20, [1.15-1.26], p=2.37e-14), and C-reactive protein (OR=1.11, [1.06-1.17], p=8.86e-14) vs. non-atypical cases. Leptin PRS was very close to the significance threshold (p=4.13e-04), but the effect disappeared when considering GWAS summary statistics of leptin adjusted for BMI. PRS for daily alcohol use was inversely associated with atypical depression (OR=0.88, [0.84-0.93], p=1.04e-05) vs. non-atypical depression. SNP-based heritability on the liability scale was not significantly different between atypical and typical depression (5.2% and 4.5%, respectively).

Conclusions: Atypical depression shows evidence of distinct genetic predisposition to immune-metabolic traits in line with the previous literature. These genetic signals suggest that biological targets including cardiometabolic or immune pathways may be germane to therapies in individuals with atypical depression.

Keywords: atypical depression, CRP, cardio-metabolic diseases, BMI, polygenic risk scores

Introduction

Depressive disorders are highly prevalent and a leading cause of global disability (James et al., 2018; Kessler & Bromet, 2013; WHO, 2017), and are associated with premature mortality (James et al., 2018; Kang et al., 2015; Kessler & Bromet, 2013; Ripke et al., 2015). Twin-based heritability (variance explained by genetic factors) of unipolar depression is estimated to be ~37% (Sullivan, Neale & Kendler, 2000), with common single-nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) explaining ~9% of variation in depression liability (Wray et al., 2018; Howard et al., 2019). Efforts to identify genetic variants associated with the disease are hindered by the heterogeneity among depressed cases, who can vary greatly in symptom presentation and severity, clinical course, and treatment response (Fried & Nesse, 2015a; Goldberg, 2011). Clinical heterogeneity may also reflect different underlying biological and causal pathways. Increasing evidence suggests that depressive symptoms and subtypes are differentially associated with genetic risk factors that overlap with other disorders (Beijers, Wardenaar, van Loo, & Schoevers, 2019; Thorp et al., 2019; Milaneschi et al., 2016; Milaneschi et al., 2017a). Investigating the clinical and genetic correlates of more homogenous subtypes may improve the understanding of specific aetiological mechanisms and the development of potential treatment targets. Similarly, identifying whether genetic risk for other disorders overlaps with certain characteristics of depression may help to elucidate biological mechanisms underlying common symptom presentations across multiple disorders.

The atypical subtype of major depression is specified in the DSM-5 by the presence of at least two of the following symptoms: hypersomnia, increased appetite and/or weight gain, leaden paralysis, and interpersonal rejection sensitivity (APA, 2013). Reversed neurovegetative symptoms (hypersomnia, increased appetite and/or weight gain), in particular, have been found to be highly specific and predictive of clinically defined atypical MDD (Benazzi, 2002). Classification of atypical depression based on reversed neurovegetative symptoms alone is often more feasible in epidemiological studies, many of which have adopted this criterion instead of the full DSM-5 criteria (Lee et al., 2009; Matza et al., 2003). Studies defining atypical depression based on reversed neurovegetative symptoms have shown similar sociodemographic and clinical correlates as those reported for classification based on the full DSM-criteria (Benazzi, 2002).

Epidemiological studies have shown differences between atypical and non-atypical depression in sociodemographic factors, clinical features, lifestyle factors, and comorbidities. Atypical depression has been associated with earlier age of onset, female gender, and more severe and recurrent depressive episodes (Agosti & Stewart, 2001; Blanco et al., 2012; Brailean, Curtis, Davis, Dregan, & Hotopf, 2019). Findings from UK Biobank showed higher rates of smoking, social isolation, and loneliness, greater exposure to adverse life events, and lower rates of moderate physical activity among atypical cases compared to non-atypical cases (Brailean et al., 2019). Atypical depression has also been associated with higher rates of bipolar disorder and psychiatric comorbidity such as anxiety disorders, binge eating disorder, and substance abuse (Agosti & Stewart, 2001; Blanco et al., 2012; Brailean et al., 2019; Lee, Ng, & Tsang, 2009; Lojko et al., 2015). Physical health comorbidities more strongly associated with atypical cases include higher body mass index (BMI), inflammation, metabolic syndrome, and cardiovascular disease (Brailean et al., 2019; Lasserre et al., 2014; Lamers et al., 2016; Lamers et al., 2013; Milaneschi et al., 2017b). Specifically, evidence suggests stronger links between atypical features of increased appetite and/or weight (A/W) and immunometabolic dysregulations, such as BMI, C-reactive protein (CRP) and leptin (Lamers et al., 2018; Milaneschi et al., 2017b). Studies examining treatment outcomes among atypical cases report greater response to exercise and

cognitive therapy and monoamine oxidase inhibitors compared to non-atypical depression (Fournier et al., 2013; Liebowitz et al., 1988; Rethorst, Tu, Carmody, Greer, & Trivedi, 2016).

There is increasing evidence to suggest partially distinct genetic profiles among depressive subtypes. Atypical depression had higher heritability than non-specified depression in a twin study (51% vs. 42%; Edvardsen et al., 2009). SNP-based heritabilities estimated from genetic analyses were found to vary across individual depressive symptoms (h^2_{SNP} range from 3-11%), with neurovegetative symptoms showing greatest heritability (Thorp et al., 2019). A study that classified cases into subtypes according to change in neurovegetative symptoms (i.e. no change, increased appetite and/or weight gain [A/W], and decreased A/W) found similar SNP-heritability of ~10% in all groups (Milaneschi et al., 2017a). Polygenic risk scoring analyses confirmed that the increased A/W subtype had higher polygenic risk for CRP, BMI and leptin levels than the decreased A/W subtype. This is consistent with prior evidence reporting an association between polygenic risk for triglycerides and atypical depression, while decreased A/W subtype was more strongly associated with polygenic risk for schizophrenia (Milaneschi et al., 2016).

In the present study, we examined the genetic overlap between atypical depression and a range of traits and disorders using polygenic risk scores. Based on previous findings, we hypothesised that atypical depression would show higher heritability and polygenic risk for cardiologic, immune-metabolic, substance use and other psychiatric traits compared to non-atypical depression.

Materials and methods

Sample

Individuals who met lifetime criteria for major depression were drawn from the UK Biobank. The UK Biobank is a prospective population-based study of ~500,000 individuals recruited across the United Kingdom, aged between 40-69 at baseline (UK Biobank, 2007). A total of 157,387 participants completed an online Mental Health Questionnaire (MHQ) assessing self-reported psychiatric symptoms corresponding to clinical diagnostic criteria and self-reported professional diagnoses (Resource 22 on http:// http://biobank.ndph.ox.ac.uk/; Davis et al., 2020). Genome-wide genetic data has been collected on all UK Biobank participants (Bycroft et al., 2017; detailed below). All participants provided written informed consent.

Measures

Lifetime psychiatric diagnoses were assessed in the MHQ using the Composite International Diagnostic Interview Short Form (CIDI-SF; Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998). Criteria for lifetime major depressive episode were in accordance with DSM-V. The full CIDI is a validated measure of depression, demonstrated to have good concordance with direct clinical assessment (Haro et al., 2006).

Cases reporting both weight gain and hypersomnia were classified as atypical depression (N = 1854), and the remaining cases classified as non-atypical cases (N = 28,215). From the non-atypical cases, typical depression was classified according to reports of both weight loss and insomnia (N = 10,142). These definitions used the same coding conventions as those used in a previous study in the UK Biobank sample (Brailean et al., 2019).

Genotyping and quality control

Genetic data came from the full release of the UK Biobank data (N = 488,377; Bycroft et al., 2017). Genotyping was performed using two highly-overlapping arrays covering ~800,000 markers (UK Biobank Axiom Array Content Summary). Autosomal genotype data underwent centralised quality control to adjust for possible array effects, batch effects, plate effects, and departures from Hardy-Weinberg equilibrium (HWE; Bycroft et al., 2017). Variants for this analysis were limited to common variants (minor allele frequency > 0.01) that were directly genotyped. SNPs were further excluded based on missingness (> 0.02) and on HWE ($p < 10-8$). Individuals were removed for high levels of missingness (> 0.05) or abnormal heterozygosity (as defined during centralised quality control), relatedness of up to third-degree kinship (KING r < 0.044 [Manichaikul et al., 2010]), or phenotypic and genotypic gender discordance (phenotypic males with $F_X<0.9$, phenotypic females with $F_X>0.6$). Population structure within the UK Biobank cohort was assessed using principal component analysis, with Caucasians defined by 4-means clustering on the first two genetic principal components (Warren et al., 2017). Among respondents to the MHQ, 95% were of Caucasian ancestry and therefore individuals from other ancestries were excluded from further analyses to maximise statistical power. After quality control, the final sample of respondents to the MHQ consisted of 126,522 individuals with genotype data.

Statistical analysis

Polygenic risk scores

Polygenic risk scores were calculated based on GWAS summary statistics for 21 traits reflecting the hypothesis formulated in the Introduction, including major psychiatric disorders, personality traits, alcohol daily use, number of cigarettes per day, lifetime cannabis use, cardio-metabolic traits and C-reactive protein (CRP). Details on these studies and the references to the corresponding papers are in Supplementary Table 1. There was no overlap between the samples included in these GWASs and the sample included in this study, except a very marginal overlap with the GWAS of anorexia nervosa (349/16,992 (2%) of cases included in Watson et al. (2019)).

PRS were calculated for each participant using PRSice v.2 (Chang et al., 2015; Choi & O'Reilly, 2019; Euesden, Lewis, & O'Reilly, 2015). PRSice computes scores in an independent (target) sample by calculating the weighted sum of trait-associated alleles using summary data from GWAS discovery samples. SNPs in linkage disequilibrium (r2 ≥ 0.1 [250-kb window]) were removed using the clumping procedure in PLINK v.1.9 (Chang et al., 2015). We used the default average option that calculates the ratio between the PRS and the number of alleles included in each individual and PRS were standardised (mean=0, SD=1). PRS were calculated at 11 p-value thresholds P_T (5e-8, 1e-5, 1e-3, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1) and the most predictive P_T was selected. Logistic regression models were used to estimate associations between atypical depression vs. non-atypical depression and each PRS adjusting for covariates of six genetic ancestry principal components, centre and batch effects. The proportion of variance explained by PRS on the liability scale was estimated according to Lee et al. (Lee et al., 2012), considering a prevalence of 27% of atypical depression among depressed cases (see references in the next paragraph). For PRS of traits associated with atypical depression we calculated the OR of atypical vs. non-atypical depression for each decile of the PRS distribution, taking the first decile as reference, and we tested if the strength of the PRS effect changed when comparing atypical depression with healthy controls who completed the MHQ (n=64,604).

A Bonferroni correction was applied to account for multiple testing, providing a required significance level of $p < 2.2e-04$ (the PRS of 16 traits were analysed at 11 P_T, while for 5 traits there were no SNPs with $p < 5e-8$ and 10 thresholds were tested [0.05/(11 x 16 + 10 x 5)= 2.2e-04]). The use of Bonferroni correction is conservative, since the different P_T are highly correlated.

SNP-based heritability

Using genome-wide complex trait analysis software v.1.92.4beta (GCTA; Yang et al., 2011), genetic relationship matrix-restricted maximum likelihood (GREML) methods (Lee et al., 2011) were used to estimate the variance in liability to atypical and typical depression subtypes attributable to the additive effects of all SNPs. A random subset of 8,000 healthy controls were selected for the analyses among those who completed the MHQ. This number of controls was selected because it provided adequate power (at least 80%) to estimate heritability considering the prevalence of depression subtypes in UK Biobank and an expected heritability of 0.10 (Milaneschi et al., 2017a), using GCTA-GREML Power Calculator (Visscher et al., 2014). SNP-based heritability estimates were transformed to a normally distributed liability scale to allow comparisons across different phenotypes and populations (Lee et al., 2011). Transformation to the liability scale allows comparisons with the existing literature. Based on the literature, we assumed a population prevalence of 3.48% for atypical depression (Lojko & Rybakowski, 2017) and 9.28% for typical depression (Levitan et al., 1997).

Sensitivity analyses

Analyses were repeated 1) excluding cases with probable bipolar disorder (wider definition, as described in Brailean et al., 2019, n=1747) and 2) comparing atypical depression with typical depression (rather than non-atypical depression), see Figure 1.

Results

Sample characteristics

The total sample comprised of 30,069 UK Biobank participants who met criteria for lifetime major depressive episode, including 1,854 cases classified as atypical depression and 28,215 classified as non-atypical depression. Non-atypical cases were further classified as typical depression (N = 10,142). The atypical group was 75% female and had a mean age of 59.99 (*SD* = 7.09) years, compared to the non-atypical group which was 68% female and had a mean age of 62.50 (7.53) years. The typical depression group was 75% female and had a mean age of 62.55 (7.49). Further description of the clinical-demographic features of the subtypes can be found in a previous paper in UK biobank that used the same classification criteria (Brailean et al., 2019).

Polygenic risk analysis

Traits where the PRS were significantly associated with atypical depression compared to non-atypical depression included body mass index (BMI, OR=1.20 [1.15 − 1.26], p=2.37e-14), CRP (OR=1.11 [1.06 − 1.17], p=8.86e-06) and daily alcohol use (OR=0.88 [0.84 − 0.93], p=1.04e-05), as shown in Table 1. The OR for atypical depression was 2.03 (1.62-2.55), 1.36 (1.10- 1.68) and 0.62 (0.49-0.79) in the 10th PRS decile vs. the 1st PRS decile for BMI, CRP and daily alcohol use, respectively (Figure 2). Results were consistent between different P_T (Supplementary Figure 1). The effect of BMI PRS was similar when comparing atypical depression with healthy controls (P_T=0.3, OR=1.24 [1.18-1.30], p=1.65e-18), as well as the effect of CRP PRS (P_T=0.4, OR=1.13 [1.08-1.19], p=6.11e-07) and daily alcohol use PRS (P_T=0.2, OR=0.88 [0.84-0.93], p=9.31e-06). For comparison, we report that the effect of BMI PRS was smaller (z test with results of atypical depression vs. healthy controls: z=7.36, p=1.82e-13) when comparing non-atypical depression vs. healthy controls (P_T=0.4, OR=1.03 [1.01-1.04], p=1.15e-05), while CRP PRS and daily alcohol use PRS had no effect (p=0.01 and p=0.02, respectively).

The association between atypical vs. non-atypical depression and leptin PRS was very close to the significance threshold (OR=1.09 [1.04 – 1.14], p=4.13e-04) but disappeared when considering GWAS summary statistics of leptin adjusted for BMI. Nominal significant associations (i.e. p < 0.05) included PRS for alcohol dependence, PTSD, type 2 diabetes, coronary artery disease, triglycerides, total HDL cholesterol, and ischemic stroke (Figure 3; Supplementary Table 2). Sensitivity analysis revealed very similar results when excluding cases with probable bipolar disorder (n=196 among patients with atypical depression [6.3%] and n=1551 among those with non-atypical depression [5.5%]; not shown). Results were mostly similar when comparing atypical vs. typical groups, except that BMI PRS had a stronger effect on atypical depression risk (P_T=0.001, OR=1.27 [1.21-1.34], p=1.80e-20), but not significantly different for the comparison atypical vs. non-atypical depression (z=1.68, p=0.11).

SNP-based heritability

SNP-based heritability (h^2_{SNP}) on the liability scale was estimated to be 0.052 (SE=0.012, 95% CI=0.028-0.076, p=5.06e-06) for atypical depression and 0.045 (SE=0.0087, 95% CI=0.028-0.062, p=1.84e-08) for typical depression. Estimates were similar after excluding cases with bipolar disorder for both atypical depression (h^2_{SNP} = 0.057, SE=0.013, 95% CI=0.032-0.082, p=2.08e-06) and typical depression (h^2_{SNP} = 0.043, SE=0.009, 95% CI=0.025-0.061, p=1.43e-07) (Supplementary Table 3).

Discussion

This study examined the genetic overlap between atypical depression and a range of traits and disorders using polygenic risk scores in 30,069 cases with major depression from the UK Biobank. The findings showed that persons with higher BMI PRS and CRP PRS are more likely to have atypical depression vs. non-atypical depression, while those with lower PRS for alcohol daily use were more likely to have non-atypical depression rather than atypical depression. Associations with these PRS were consistent among different P_T (Supplementary Figure 1), with BMI PRS showing a lower P_T as best threshold, probably because the original GWAS had larger sample size compared to the other traits, thus more power (Dudbridge, 2013). The effect of BMI PRS and CRP PRS on the risk of atypical depression was similar when taking healthy controls as comparator group, while it was significantly lower or absent, respectively, when we compared non-atypical cases vs. healthy controls. These findings suggest that non-atypical depression cases are more similar to controls than to atypical cases for these two PRS. In line with higher BMI and CRP PRS in atypical cases, PRS for several cardio-metabolic traits (e.g. type 2 diabetes, coronary artery disease and ischemic stroke) showed nominal positive associations with atypical depression. Comparing atypical with typical cases of depression (i.e. increased vs. decreased weight gain and hypersomnia) yielded similar results, indicating that atypical depression did not show a different genetic profile just because the use of more conditions in the selection criteria identified more extreme phenotypes. The exclusion of cases with bipolar disorder did not change the results either, suggesting that the observed findings were independent from disease polarity (unipolar or bipolar).

Taken together, these findings suggest partially distinct genetic pathways underlying atypical and non-atypical subtypes of depression and that this divergence may be attributable to distinct genetic predisposition to immune-metabolic traits in atypical depression. The SNP-based heritability was estimated to be similar between atypical depression and typical depression (h^2_{SNP} = 5.2% and 4.5%, respectively), and it did not significantly change after excluding cases with probable bipolar disorder (h^2_{SNP} = 5.7% and 4.3%, respectively).

Evidence from observational studies has shown differential pathophysiological correlates among subtypes of depression, with atypical depression more strongly associated with obesity and metabolic dysregulations than non-atypical depression (Brailean et al., 2019; Lasserre et al., 2014; Lamers et al., 2016; Lamers et al., 2013; Milaneschi et al., 2017b). Consistent with previous research (Milaneschi et al., 2016; Milaneschi et al., 2017a), the present findings suggest that the phenotypic association between atypical depression and cardiometabolic traits may partly result from shared genetic and biological mechanisms. For example, pleiotropy may occur when shared genetic variants influence obesity-related traits and atypical depression through common pathways such as inflammation and/or leptin system dysregulation (Guo & Lu, 2014; Ring & Zeltser, 2010). Milaneschi et al. (2017a) reported that the genetic correlation between leptin and atypical depression was decreased but not absent when considering leptin adjusted for BMI, while we found no association between PRS for BMI-adjusted leptin levels and atypical depression. Leptin reduces food intake and obesity is associated with increased leptin levels, through the induction of leptin-resistance (Myers, Leibel, Seeley, & Schwartz, 2010). The adjustment of leptin levels for BMI eliminates an important source in leptin inter-individual variability, and separates the genetic factors regulating BMI from those that regulate only leptin production. Our results indicate that the genetic factors predisposing to increased BMI and increased leptin levels in atypical depression are highly correlated, in line with the fact that increased leptin levels are a consequence of increased BMI rather than a cause (Myers et al., 2010). This discrepancy may also relate to the different criteria used to define atypical depression: increased appetite/weight was used as only criterion for atypical depression in Milaneschi et al. (2017a), which may play a larger role in connection with leptin levels independent of BMI than other atypical symptoms (Lamers et al., 2018; Milaneschi et al., 2017b).

The current findings also showed that PRS for alcohol daily use was inversely associated with risk for atypical depression and PRS for alcohol dependence showed a nominal effect in the same direction. Epidemiological studies have shown increased alcohol consumption and/or risk of alcohol use disorders among persons with atypical depression (Blanco et al., 2012; Brailean et al., 2019; Gili et al., 2012). There are no previous studies which examined the genetic overlap between alcohol use and atypical depression, although a positive genetic association between unipolar depression and alcohol dependence has been reported (Andersen et al., 2017; Foo et al., 2018). Our results suggest that genetic risk for alcohol use is lower in atypical depression vs non-atypical depression, in contrast with epidemiological observations. A possible hypothesis explaining this finding is that the increased rate of alcohol use among cases with atypical depression may result from secondary or environmental risk factors rather than from a genetic aetiology. In line with this hypothesis, atypical depression cases in UK Biobank show longer, more severe and recurrent disease episodes, increased risk of comorbidities, and more lifetime deprivation and adversity (Brailean et al., 2019), and these factors may be responsible for increased risk of alcohol use disorders (Yang et al., 2018).

Several limitations should be considered when interpreting the results from the present study. First, the UK Biobank is not representative of the general population, with respondents more likely to be older, female, healthier, of a higher socioeconomic background, and better educated (Fry et al., 2017). Compared to the overall UK Biobank cohort, respondents of the MHQ have on average higher educational and occupational attainment, are less likely to smoke, or report longstanding illness/disability (Davis & Hotopf, 2019). This is likely to impact on prevalence and severity of depression within the sample, with persons with severe depression less likely to have completed the MHQ. Second, measures for depression were based on recall of the worst previous episode of depression and assessed using self-reported symptoms, rather than clinical diagnoses. This raises the possibility that self-reported symptoms may be affected by recall bias or other medical conditions, and we are not able to exclude that participants had other depressive episodes with different

characteristics compared to the one reported in the MHQ. Third, our measurement of atypical depression did not capture all DSM-5 symptoms. Nevertheless, our findings are largely consistent with prior evidence from observational and genetic studies and the less exacting definition of atypical depression used here may have diluted underlying associations. Last, due to the small numbers of individuals of non-Caucasian groups in UK biobank, and their systematic under-representation in GWAS studies used to derive PRS, our sample is limited to individuals of Caucasian descent, limiting the generalisability of our findings.

In conclusion, this study showed specific genetic overlap between atypical depression and immune-metabolic traits based on polygenic risk scores. Our findings suggest that atypical depression may represent a relatively homogenous subtype characterised by partially distinct genetic liabilities. Establishing specific biological mechanisms associated with subtypes of depression may have clinical implications, with the potential for improved diagnosis, prognosis and personalised treatments. In addition, understanding the shared genetic aetiology between immune-metabolic traits and atypical depression could play an important role in the prevention/treatment of depressive episodes and the development of tailored treatments.

Acknowledgements

This research was supported by the UK Medical Research Council (MR/N015746/1). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

The authors acknowledge use of the research computing facility at King's College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy's & St. Thomas' NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy's & St. Thomas' Charity (TR130505).

UK Biobank data was accessed under application 18177 "Multi-trait GWAS analyses in the UK Biobank".

Conflict of interest

Cathryn Lewis is a member of the Scientific Advisory Board of Myriad Neurosciences. Matthew Hotopf is principal investigator of RADAR-CNS (funded by European Commission, Janssen, Biogen, UCB, MSD and Lundbeck). The other authors declare no potential conflict of interest.

References

1. Agosti, V., & Stewart, J. W. (2001). Atypical and non-atypical subtypes of depression: Comparison of social functioning, symptoms, course of illness, co-morbidity and demographic features. *Journal of Affective Disorders*, *65*(1), 75–79. https://doi.org/10.1016/s0165-0327(00)00251-2

2. American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders*

(Fifth Edition). American Psychiatric Association.
https://doi.org/10.1176/appi.books.9780890425596

3. Andersen, A. M., Pietrzak, R. H., Kranzler, H. R., Ma, L., Zhou, H., Liu, X., Kramer, J., Kuperman, S., Edenberg, H. J., Nurnberger, J. I., Rice, J. P., Tischfield, J. A., Goate, A., Foroud, T. M., Meyers, J. L., Porjesz, B., Dick, D. M., Hesselbrock, V., Boerwinkle, E., … Han, S. (2017). Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence. *JAMA Psychiatry*, *74*(11), 1153–1160. https://doi.org/10.1001/jamapsychiatry.2017.2269

4. Beijers, L., Wardenaar, K. J., Loo, H. M. van, & Schoevers, R. A. (2019). Data-driven biological subtypes of depression: Systematic review of biological approaches to depression subtyping. *Molecular Psychiatry*, *24*(6), 888–900. https://doi.org/10.1038/s41380-019-0385-5

5. Benazzi, F. (2002). Can only reversed vegetative symptoms define atypical depression? *European Archives of Psychiatry and Clinical Neuroscience*, *252*(6), 288–293. https://doi.org/10.1007/s00406-002-0395-0

6. Biobank, U. K. (2007). Protocol for a large-scale prospective epidemiological resource. Protocol No: UKBB-PROT-09-06 (Main Phase).

7. Blanco, C., Vesga-López, O., Stewart, J. W., Liu, S.-M., Grant, B. F., & Hasin, D. S. (2012). Epidemiology of major depression with atypical features: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *The Journal of Clinical Psychiatry*, *73*(2), 224–232. https://doi.org/10.4088/JCP.10m06227

8. Brailean, A., Curtis, J., Davis, K., Dregan, A., & Hotopf, M. (2019). Characteristics, comorbidities, and correlates of atypical depression: Evidence from the UK Biobank Mental Health Survey. *Psychological Medicine*, 1–10. https://doi.org/10.1017/S0033291719001004

9. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., McVean, G., Leslie, S., Donnelly, P., & Marchini, J. (2018). Genome-wide genetic data on ~500,000 UK Biobank participants. *Nature*, *562*, 203-209. https://doi.org/10.1038/s41586-018-0579-z

10. Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015). Second-generation PLINK: Rising to the challenge of larger and richer datasets. *GigaScience*, *4*, 7. https://doi.org/10.1186/s13742-015-0047-8

11. Choi, S. W., & O'Reilly, P. F. (2019). PRSice-2: Polygenic Risk Score software for biobank-scale data. *GigaScience, 8(7),* 1-6. https://doi.org/10.1093/gigascience/giz082

12. Davis, K., & Hotopf, M. (2019). Mental health phenotyping in UK Biobank. *Progress in Neurology and Psychiatry*, *23(1),* 4–7. https://doi.org/10.1002/pnp.522

13. Davis, K.A.S., Coleman, J.R.I., Adams, M., Allen, N., Breen, G., Cullen, B., … Hotopf, M. (2020). Mental Health in UK Biobank – development, implementation and results from an online questionnaire completed by 157,366 participants: a reanalysis. *BJPsych Open, 6(2),* e18. https://doi.org/10.1192/bjo.2019.100

14. Dudbridge, F. (2013). Power and predictive accuracy of polygenic risk scores. *PLoS Genetics, 9(3),* e1003348. https://doi.org/10.1371/journal.pgen.1003348

15. Edvardsen, J., Torgersen, S., Røysamb, E., Lygren, S., Skre, I., Onstad, S., & Øien, P. A. (2009). Unipolar depressive disorders have a common genotype. *Journal of Affective Disorders*, *117*(1–2), 30–41. https://doi.org/10.1016/j.jad.2008.12.004

16. Euesden, J., Lewis, C. M., & O'Reilly, P. F. (2015). PRSice: Polygenic Risk Score software. *Bioinformatics (Oxford, England)*, *31*(9), 1466–1468. https://doi.org/10.1093/bioinformatics/btu848

17. Foo, J. C., Streit, F., Treutlein, J., Ripke, S., Witt, S. H., Strohmaier, J., Degenhardt, F., Forstner, A. J., Hoffmann, P., Soyka, M., Dahmen, N., Scherbaum, N., Wodarz, N., Heilmann-Heimbach, S., Herms, S., Cichon, S., Preuss, U., Gaebel, W., Ridinger, M., … Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. (2018). Shared genetic etiology between alcohol dependence and major depressive disorder. *Psychiatric Genetics*, *28*(4), 66–70. https://doi.org/10.1097/YPG.0000000000000201

18. Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Gallop, R., Shelton, R. C., & Amsterdam, J. D. (2013). Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. *Behaviour Research and Therapy*, *51*(7), 392–398. https://doi.org/10.1016/j.brat.2013.03.010

19. Fried, E. I., & Nesse, R. M. (2015). Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. *Journal of Affective Disorders*, *172*, 96–102. https://doi.org/10.1016/j.jad.2014.10.010

20. Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., & Allen, N. E. (2017). Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *American Journal of Epidemiology*, *186*(9), 1026–1034. https://doi.org/10.1093/aje/kwx246

21. Gili, M., Roca, M., Armengol, S., Asensio, D., Garcia-Campayo, J., & Parker, G. (2012). Clinical Patterns and Treatment Outcome in Patients with Melancholic, Atypical and Non-Melancholic Depressions. *PLoS ONE*, *7*(10). https://doi.org/10.1371/journal.pone.0048200

22. Goldberg, D. (2011). The heterogeneity of "major depression." *World Psychiatry*, *10*(3), 226–228. https://doi.org/10.1002/j.2051-5545.2011.tb00061.x

23. Guo, M., & Lu, X.-Y. (2014). Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates. *Translational Psychiatry*, *4*, e486. https://doi.org/10.1038/tp.2014.126

24. Haro, J. M., Arbabzadeh-Bouchez, S., Brugha, T. S., de Girolamo, G., Guyer, M. E., Jin, R., Lepine, J. P., Mazzi, F., Reneses, B., Vilagut, G., Sampson, N. A., & Kessler, R. C. (2006). Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. *International Journal of Methods in Psychiatric Research*, *15*(4), 167–180. https://doi.org/10.1002/mpr.196

25. Howard, D. M., Adams, M. J., Shirali, M., Clarke, T.-K., Marioni, R. E., Davies, G., Coleman, J. R. I., Alloza, C., Shen, X., Barbu, M. C., Wigmore, E. M., Gibson, J., Hagenaars, S. P., Lewis, C. M., Ward, J., Smith, D. J., Sullivan, P. F., Haley, C. S., Breen, G., … McIntosh, A. M. (2018). Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory

synaptic pathways. *Nature Communications*, *9*(1), 1–10. https://doi.org/10.1038/s41467-018-03819-3

26. James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., … Murray, C. J. L. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*, *392*(10159), 1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7

27. Kang, H.-J., Kim, S.-Y., Bae, K.-Y., Kim, S.-W., Shin, I.-S., Yoon, J.-S., & Kim, J.-M. (2015). Comorbidity of Depression with Physical Disorders: Research and Clinical Implications. *Chonnam Medical Journal*, *51*(1), 8–18. https://doi.org/10.4068/cmj.2015.51.1.8

28. Kessler, R. C., Andrews, G., Mroczek, D., Ustun, B., & Wittchen, H.-U. (1998). The World Health Organization Composite International Diagnostic Interview short-form (CIDI-SF). *International Journal of Methods in Psychiatric Research*, *7*(4), 171–185. https://doi.org/10.1002/mpr.47

29. Kessler, R. C., & Bromet, E. J. (2013). The epidemiology of depression across cultures. *Annual Review of Public Health*, *34*, 119–138. https://doi.org/10.1146/annurev-publhealth-031912-114409

30. Lamers, F., Beekman, A. T. F., Hemert, A. M. van, Schoevers, R. A., & Penninx, B. W. J. H. (2016). Six-year longitudinal course and outcomes of subtypes of depression. *The British Journal of Psychiatry*, *208*(1), 62–68. https://doi.org/10.1192/bjp.bp.114.153098

31. Lamers, F., Milaneschi, Y., de Jonge, P., Giltay, E. J., & Penninx, B. W. J. H. (2018). Metabolic and inflammatory markers: Associations with individual depressive symptoms. *Psychological Medicine*, *48*(7), 1102–1110. https://doi.org/10.1017/S0033291717002483

32. Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013). Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. *Molecular Psychiatry*, *18*(6), 692–699. https://doi.org/10.1038/mp.2012.144

33. Lasserre, A. M., Glaus, J., Vandeleur, C. L., Marques-Vidal, P., Vaucher, J., Bastardot, F., Waeber, G., Vollenweider, P., & Preisig, M. (2014). Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: A prospective, population-based study. *JAMA Psychiatry*, *71*(8), 880–888. https://doi.org/10.1001/jamapsychiatry.2014.411

34. Lee, S. H., Goddard, M. E., Wray, N. R., & Visscher, P. M. (2012). A Better Coefficient of Determination for Genetic Profile Analysis. *Genetic Epidemiology*, *36*(3), 214–224. https://doi.org/10.1002/gepi.21614

35. Lee, S. H., Wray, N. R., Goddard, M. E., & Visscher, P. M. (2011). Estimating Missing Heritability for Disease from Genome-wide Association Studies. *American Journal of Human Genetics*, *88*(3), 294–305. https://doi.org/10.1016/j.ajhg.2011.02.002

36. Lee, S., Ng, K. L., & Tsang, A. (2009). Prevalence and correlates of depression with atypical symptoms in Hong Kong. *The Australian and New Zealand Journal of Psychiatry*, *43*(12), 1147–1154. https://doi.org/10.3109/00048670903279895

37. Levitan, R. D., Lesage, A., Parikh, S. V., Goering, P., & Kennedy, S. H. (1997). Reversed neurovegetative symptoms of depression: A community study of Ontario. *The American Journal of Psychiatry*, *154*(7), 934–940. https://doi.org/10.1176/ajp.154.7.934

38. Liebowitz, M.R., Quitkin, M.F., Stewart, J.W., McGrath, P.J., Harrison, W.M., Markowitz, J.S. … Klein, D.F. (1988). Antidepressant specificity in atypical depression. *Arch Gen Psychiatry, 45(2),* 129-137. https://doi.org/10.1001/archpsyc.1988.01800260037004

39. Łojko, D., Buzuk, G., Owecki, M., Ruchała, M., & Rybakowski, J. K. (2015). Atypical features in depression: Association with obesity and bipolar disorder. *Journal of Affective Disorders*, *185*, 76–80. https://doi.org/10.1016/j.jad.2015.06.020

40. Łojko, D., & Rybakowski, J. K. (2017). Atypical depression: Current perspectives. *Neuropsychiatric Disease and Treatment*, *13*, 2447–2456. https://doi.org/10.2147/NDT.S147317

41. Manichaikul, A., Mychaleckyj, J. C., Rich, S. S., Daly, K., Sale, M., & Chen, W.-M. (2010). Robust relationship inference in genome-wide association studies. *Bioinformatics (Oxford, England)*, *26*(22), 2867–2873. https://doi.org/10.1093/bioinformatics/btq559

42. Matza, L. S., Revicki, D. A., Davidson, J. R., & Stewart, J. W. (2003). Depression with atypical features in the National Comorbidity Survey: Classification, description, and consequences. *Archives of General Psychiatry*, *60*(8), 817–826. https://doi.org/10.1001/archpsyc.60.8.817

43. Milaneschi, Y., Lamers, F., Peyrot, W. J., Abdellaoui, A., Willemsen, G., Hottenga, J.-J., Jansen, R., Mbarek, H., Dehghan, A., Lu, C., CHARGE inflammation working group, Boomsma, D. I., & Penninx, B. W. J. H. (2016). Polygenic dissection of major depression clinical heterogeneity. *Molecular Psychiatry*, *21*(4), 516–522. https://doi.org/10.1038/mp.2015.86

44. Milaneschi, Yuri, Lamers, F., Bot, M., Drent, M. L., & Penninx, B. W. J. H. (2017b). Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. *Biological Psychiatry*, *81*(9), 807–814. https://doi.org/10.1016/j.biopsych.2015.10.023

45. Milaneschi, Yuri, Lamers, F., Peyrot, W. J., Baune, B. T., Breen, G., Dehghan, A., … CHARGE Inflammation Working Group and the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. (2017a). Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry*, *74*(12), 1214–1225. https://doi.org/10.1001/jamapsychiatry.2017.3016

46. Myers, M. G., Leibel, R. L., Seeley, R. J., & Schwartz, M. W. (2010). Obesity and leptin resistance: Distinguishing cause from effect. *Trends in Endocrinology and Metabolism: TEM*, *21*(11), 643–651. https://doi.org/10.1016/j.tem.2010.08.002

47. Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013). A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. *JAMA Psychiatry*, *70*(1), 31–41. https://doi.org/10.1001/2013.jamapsychiatry.4

48. Rethorst, C. D., Tu, J., Carmody, T. J., Greer, T. L., & Trivedi, M. H. (2016). Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. *Journal of Affective Disorders*, *200*, 156–158. https://doi.org/10.1016/j.jad.2016.01.052

49. Ring, L. E., & Zeltser, L. M. (2010). Disruption of hypothalamic leptin signaling in mice leads to early-onset obesity, but physiological adaptations in mature animals stabilize adiposity levels. *The Journal of Clinical Investigation*, *120*(8), 2931–2941. https://doi.org/10.1172/JCI41985

50. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature*, *511*(7510), 421–427. https://doi.org/10.1038/nature13595

51. Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiology of major depression: Review and meta-analysis. *The American Journal of Psychiatry*, *157*(10), 1552–1562. https://doi.org/10.1176/appi.ajp.157.10.1552

52. Thorp, J. G., Marees, A. T., Ong, J.-S., An, J., MacGregor, S., & Derks, E. M. (2019). Investigating Genetic Heterogeneity in Major Depression Through Item-level Genetic Analyses of the PHQ-9. *BioRxiv*, 528067. https://doi.org/10.1101/528067

53. Visscher, P. M., Hemani, G., Vinkhuyzen, A. A. E., Chen, G.-B., Lee, S. H., Wray, N. R., Goddard, M. E., & Yang, J. (2014). Statistical Power to Detect Genetic (Co)Variance of Complex Traits Using SNP Data in Unrelated Samples. *PLOS Genetics*, *10*(4), e1004269. https://doi.org/10.1371/journal.pgen.1004269

54. Warren, H. R., Evangelou, E., Cabrera, C. P., Gao, H., Ren, M., Mifsud, B., … UK Biobank CardioMetabolic Consortium BP working group. (2017). Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nature Genetics*, *49*(3), 403–415. https://doi.org/10.1038/ng.3768

55. World Health Organisation. (2017). Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: Switzerland. https://apps.who.int/iris/handle/10665/254610

56. Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., ... & Bacanu, S. A. (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature Genetics*, *50(5),* 668-681. https://doi.org/10.1038/s41588-018-0090-3

57. Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011). GCTA: A Tool for Genome-wide Complex Trait Analysis. *American Journal of Human Genetics*, *88*(1), 76–82. https://doi.org/10.1016/j.ajhg.2010.11.011

58. Yang, P., Tao, R., He, C., Liu, S., Wang, Y., & Zhang, X. (2018). The Risk Factors of the Alcohol Use Disorders—Through Review of Its Comorbidities. *Frontiers in Neuroscience*, *12*. https://doi.org/10.3389/fnins.2018.00303

Table 1. Polygenic risk scores associated with atypical depression. Results are shown for the P_T threshold attaining the lowest p-value.

Polygenic Risk Score	Reference	Sample size	P_T	p	OR (95% CI)	R^2
BMI	Locke et al. (2015)	322,154	0.001	2.37e-14*	1.20 (1.15 – 1.26)	0.0118
Leptin	Kilpeläinen et al. (2016)	31,816	0.3	4.13e-04	1.09 (1.04 – 1.14)	0.0025
CRP	Ligthart et al. (2018)	204,402	0.4	8.86e-06*	1.11 (1.06 – 1.17)	0.0040
Daily alcohol use	Schumann et al. (2016)	70,460	0.4	1.04e-0.5*	0.88 (0.83 – 0.93)	0.0039

Note. R^2 estimated on the liability scale. *Significant associations ($p < 2.2e-04$).

Figure 1: flow chart of the performed analyses.

Figure 2: Decile plots showing the odds ratio of atypical depression vs. non-atypical depression for BMI PRS (A), C-reactive protein (CRP) PRS (B) and daily alcohol use PRS (C). *p<0.05; **p<1e-05.

C. Daily alcohol use

Figure 3: odds ratio (OR) and 95% confidence intervals of atypical vs. non-atypical depression for the analysed PRS. BP=bipolar disorder; SCZ=schizophrenia; ANX=anxiety disorders; PTSD=post-traumatic stress disorder; AN=anorexia nervosa; ALCDEP=alcohol dependence; ALCUSE=daily alcohol use; N_CIGARETTES=n cigarettes per day; CANN=cannabis use lifetime; EXTR=extraversion; NEU=neuroticism; DM2=type 2 diabetes mellitus; CAD= coronary artery disease; ISCH_STROKE=ischemic stroke; TG= triglycerides; LDL=total LDL cholesterol; HDL=total HDL cholesterol; BMI=body max index; BMI_adjust_leptin=leptin adjusted for BMI; CRP=C-reactive protein.